KATHLEEN TELL THE FREAKING TRUTH FOR A CHANGE! STOP YOUR LIES YOU'RE AS BAD AS KARL ROVE AND GEORGE W BUSH!@

ANSWER THE QUESTIONS KATHLEEN


Let's see how you like it kathleen EVERY time you post, I will change
the title of the thread and I will post these questions until you
answer them one by one and answering them means NOT talking about
mcsweegan or former governor rowland and all your typical diversionary
crap anyway.


PLUS you are cross posting ONCE AGAIN TOTALLY OFF TOPIC and you're
selfish to do this to one newsgroups CRIMINAL to do it to multiple
newsgroups--yes here is your "crime": You are preventing people who
need help from getting help for your selfish personal reasons that you
are so completely egocentric along with delusional paranoid
schizophrenic with psychotic features that you just can't see past your



own twisted delusional psychotic personal agenda--which ought to be
about getting your kids back and solving your own enormous problems in
life instead of trying to solve anyone else's. By preventing people
from getting help you are responsible for the consequences. Surely
people are dying as a result so you are a murderer (trying out a little



kathleen "logic" here. So you are now being reported to the DOJ FBI and



CIA and WHO and UN and DCF and the federal and state courts and
homeland insanity department and all over the planet as a murderer.


How do you like them apples?


Now answer the questions. And stop the off topic cross posting. Answer
the questions TRUTHFULLY for a change. Focus on the question. If
there's a question yuo don't understand which is hard to believe given
your self declared genius IQ, let us know and we'll rephrase it.


Don't LIE as you do and don't try your diversionary tactics. Ignore
this and I will keep reposting it kathleen. Not only that but your
silence will be construed as admissions to all of the facts listed as
questions.


PS: This is NOT "taunting" You have put your credibility at issue. You
have repeatedly said that you NEVER lie. We deserve the answers to
these questions. Straight answers.


REPOST:


http://groups-beta.google.com/group/sci.med.diseases.lyme/browse_thre...



Nope we're talking about YOU. ANSWER THE QUESTIONS


And come back and tell us when Steere or McSweegan or anyone else is
actually charged with your "Lyme Crymes" instead of telling us what
you, in all your infinite wisdom, think will happen.


Now let's talk not about who WILL be convicted but WHO already has
been--YOU.


Here's the question list. One by one give us some answers. Your post is



just like the Bush White House trying to DIVERT attention from what
Karl Rove did to Joe Wilson--by attacking him AGAIN.


Nope answer the questions kathleen. Stop trying to change the subject.
I know you're delusional but try to focus. Here is a list of questions
for YOU. We've already heard your ramblings about 100,000 times. Now
dish some TRUTH for a change--I'm going to leave space between the
questions for your answers:


Was your case appealed and was your conviction overturned?


And what isn't true? Everything can be backed up with your own posts
kathleen. Not a big secret how people know since you posted it all
here.


Were you charged with and convicted of threatening and harassing
Jessica Gauvin?


Did you flee to Canada?


Did you tell everyone that your case was a custody case against DCF
when the truth was that it was a criminal case against you and your
kids had been taken away many months earlier and you didn't even appeal



that?


Did you threaten to bomb the stonington schools, joke or not?


Did you show up at your kid's safe house with a bag full of drugs
whether you meant to give them to your lawyer or not?


Come on specifically what isn't true?


You were charged tried and convicted in a court of law. Right or wrong,



admit or deny?


Now you say you've proven you're innocent.


In what court were your convictions overturned?


In fact, tell us what the charges were. Give some detail. What exactly
were you convicted of doing or threatening to do to Jessica Gauvin?


Tell us what your diagnosis was in the mental institution?


You admit or deny that your kids were taken away by child services in
CT?


Admit or deny you were charged with crimes?


Admit or deny you feld to canada?


Admit or deny you were convicted?


Admit or deny you were institutionalized in a mental ward locked wing?


Admit or deny that your convictions were never reversed, in fact you
never filed an appeal did you?


So who's lying about what?


Yeah sure, you say everyone lied about the charges. But that's not what



the court thought was it?


Did you register a website claiming on it you were working for Pfizer
at the time when you had "retired" years before?


Was Lymeraft which solicited funds for YOU, ever a proper legally
registered charity?


kathleen you're the liar here.


Do you really expect everyone to believe that the rest of the world is
crazy, not you?


And that the rest if the world has conspired to frame you? Because of
your lyme activism which you have even admitted amounts to more posting



on the internet than any real accomplishments?


Come on kathleen. What isn't true specifically issue by issue above.
Tell us specifically which items you say aren't true. We can go back
and find the posts where you admitted stuff and show what a liar YOU
are!




kathleen wrote:
> The key to the Lyme cryme:
>
> Steere used a high passage version of Bb
> strain G39/40 which had lowered expression
> of the OspA and B plasmid (and others) to
> concoct the silly CDC Dressler/Steere
> IgG standard for Lyme.
>
> That was how OspA and B were left out
> of the CDC Dearborn Dressler/Steere standard,
> http://www.cdc.gov/mmwr/preview/mmwrhtml/00038469.htm
>
> since the crime was about Yale's passing off
> a bogus Lyme vaccine and then getting all the
> national testing for Lyme thru their "partnership"
> with Corixa, L2 Diagnostics Imugen, and SmithKline.
>
> The testing for Lyme is bogus, and thus the LymeRIX
> and ImmuLyme trials were bogus.
>
>
> The www.ALDF.com did not want anyone to know
> that they should be treated on tick attachment
> because during the vaccine trials, if treatment
> on tick bite was the standard of care, then
> no one would know if LymeRIX or antibiotic
> prevented Lyme. But they suppressed this
> information even though if you wait for
> the rash to show up, in 2/3 of the people,
> their brains will already be infected permanently.
>
> They (ALDF, Durland Fish, Edward McSweegan) suppressed
> this information for 9 years. DELIBERATELY.
>
> As an aside:
> http://en.wikipedia.org/wiki/Paul_Wolfowitz
>
> "From 1970-72 Wolfowitz taught at Yale University where
> one of his students was Lewis Libby who would become a
> long-term political associate."
>
> Lewis Libby being the other CIA Plame name leaker.
>
> Adding more to the intrigue.
>
> "The PNAC advocated preemptive U.S. military intervention against Iraq
> and other "potential aggressor states" to "protect our vital interests
> in the Gulf"."
>
> One of which would be Israel. The US and Israel have
> biodevelopment agreements. Zuckerman was a candidate
> for Ambassador to Israel. Zuckerman showed up at the
> ALDF GALA, at the Pierre Hotel in NYC, but then got back
> in his limo and drove away once he saw our protest.
>
> YOU DECIDE.
>
> I have decided that Yale, ALDF and related Weld-Bush-Zuckerman
> crooks have too much CIA "information" that they are "using" to
> their financial advantage, that is tantamount to treason.
> -------------------------------
>
> 1) Lyme is a borreliosis (a permanent brain infection), and we're not
> "CRAZY"
>
> Alan Barbour:
> http://www.ucihs.uci.edu/microbio/index.html?top.html&menu.html&facultyResearch/faculty/barbour.html
> "These tick-borne infections are notable for multiphasic antigenic
> variation through DNA recombinations in the case of relapsing fever,
> the occurrence of chronic arthritis in the case of Lyme disease, and
> invasion of and persistence in the brain in the case of both
> diseases."
>
> Borrelia and Brain (MedLine): (nearly 200 citations)
>
> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28%22borrelia%22%5BMeSH%20Terms%5D%20OR%20borrelia%5BText%20Word%5D%29%20AND%20%28%22brain%22%5BMeSH%20Terms%5D%20OR%20brain%5BText%20Word%5D%29
>
>
> 2) The blood testing standard for Lyme is bogus. Steere knows there
> is a different antibody profile for neuroborreliosis, and that OspA
> (LymeRIX) and B produced strong antibodies in people with arthritis, so
> it never should have been left out of the standard.
>
> Borrelia is a "stealth pathogen," thus there is not typically a
> high antibody response.
>
>
> ALAN BARBOUR:
> http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/srchnum.htm&r=1&f=G&l=50&s1=6,719,983.WKU.&OS=PN/6,719,983&RS=PN/6,719,983
>
> "Multiclonal populations therefore can exist in an infected patient
> so that immunological defenses are severely tested if not totally
> overwhelmed."
>
>
> (1986) "Antigens of Borrelia" Allen Steere, in which he states that
> antibodies to
> borrelia include OspA and B, and that these bound strongly in persons
> with Lyme arthritis.
> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3531237&query_hl=1
>
> 1: J Clin Invest. 1986 Oct;78(4):934-9.
>
> Antigens of Borrelia burgdorferi recognized during Lyme disease.
> Appearance of a
> new immunoglobulin M response and expansion of the immunoglobulin G
> response
> late in the illness.
>
> Craft JE, Fischer DK, Shimamoto GT, Steere AC.
>
> Using immunoblots, we identified proteins of Borrelia burgdorferi bound
> by IgM
> and IgG antibodies during Lyme disease. In 12 patients with early
> disease alone,
> both the IgM and IgG responses were restricted primarily to a 41-kD
> antigen.
> This limited response disappeared within several months. In contrast,
> among six
> patients with prolonged illness, the IgM response to the 41-kD protein
> sometimes
> persisted for months to years, and late in the illness during
> arthritis, a new
> IgM response sometimes developed to a 34-kD component of the organism.
> The IgG
> response in these patients appeared in a characteristic sequential
> pattern over
> months to years to as many as 11 spirochetal antigens. The appearance
> of a new
> IgM response and the expansion of the IgG response late in the illness,
> and the
> lack of such responses in patients with early disease alone, suggest
> that B.
> burgdorferi remains alive throughout the illness.
> PMID: 3531237 [PubMed - indexed for MEDLINE]
>
>
>
> (1988) "Changes in Infectivity and Plasmid Profile of the Lyme
> Disease Spirochete..." National Institute of Allergy and Infectious
> Disease , (1988)
> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=3397175&query_hl=2
> 1: Infect Immun. 1988 Aug;56(8):1831-6.
>
> Changes in infectivity and plasmid profile of the Lyme disease
> spirochete,
> Borrelia burgdorferi, as a result of in vitro cultivation.
>
> Schwan TG, Burgdorfer W, Garon CF.
>
> Laboratory of Pathobiology, Rocky Mountain Laboratories, National
> Institue of
> Allergy and Infectious Diseases, Hamilton, Montana 59840.
>
> In vitro cultivation of Borrelia burgdorferi, the etiologic agent of
> Lyme
> spirochetosis, allows for the isolation and growth of this bacterium
> from
> infected tissues. However, continuous cultivation in modified Kelly
> medium
> causes a reduction in the number of detectable plasmids and the loss of
> infectivity in the white-footed mouse, Peromyscus leucopus. In an
> unpassaged
> culture of B. burgdorferi, nine plasmids were present, including seven
> linear
> plasmids ranging in size from 49 to 16 kilobases (kb) and two circular
> plasmids
> of 27 and 7.6 kb. The 7.6-kb circular and 22-kb linear plasmids were no
> longer
> detectable in spirochetes noninfective in white-footed mice, suggesting
> that a
> gene(s) encoding for factors responsible for infection may be present
> on one or
> more of these extrachromosomal elements. Furthermore, changes in
> spirochetal
> proteins and lipopolysaccharide-like material were observed also during
> early
> cultivation and may be related to loss of infectivity.
> PMID: 3397175 [PubMed - indexed for MEDLINE]
>
>
> NIH: Don't use high passage strains: They lose OspA and B plasmid
> expression
>
>
> (1988) European Patent Application Number 93201345.1
> Assigned to Alan Barbour, Louis Magnarelli, Sven Bergstrom
>
>
> USA Patent #
> http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/srchnum.htm&r=1&f=G&l=50&s1=5,582,990.WKU.&OS=PN/5,582,990&RS=PN/5,582,990
>
> "It has been shown that the earliest IgM antibodies formed against
> antigens of the B. burgdorferi strain B31, which was deposited in the
> American Type Culture Collection in 1983 with the accession number ATCC
> 35210, are directed against a genus-specific flagellar poly-peptide
> termed flagellin having a molecular weight of 41 kd (10) and which
> reacts with monoclonal antibody H9724 (22). IgG antibodies are also
> first directed to the 41 kd flagellin, but with advancing disease IgG
> antibodies form against other immunogens, especially against two
> abundant proteins with molecular weights of 31 kd and 34 kd. These two
> proteins, which have been denoted OspA (31 kd) and OspB (34 kd), have
> been found to be located at the B. burgdorferi surface and embedded in
> its outer fluid cell membrane (11).
>
> -OspA is meant to be a diagnostic antigen (it is now not)
>
>
> 1990 CDC Publication Lyme blood testing standard: Perform serial
> Western blots
>
>
> (1991)- Yale, Fikrig, Borrelia specific flagellin fragment is 94.4%
> accurate and does not cross react (is specific)
> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1894359&query_hl=3
> 1: Infect Immun. 1991 Oct;59(10):3531-5.
>
> Molecular characterization of the humoral response to the 41-kilodalton
> flagellar antigen of Borrelia burgdorferi, the Lyme disease agent.
>
> Berland R, Fikrig E, Rahn D, Hardin J, Flavell RA.
>
> Section of Immunobiology, Yale University School of Medicine, New
> Haven,
> Connecticut 06510.
>
> The earliest humoral response in patients infected with Borrelia
> burgdorferi,
> the agent of Lyme disease, is directed against the spirochete's 41-kDa
> flagellar
> antigen. In order to map the epitopes recognized on this antigen, 11
> overlapping
> fragments spanning the flagellin gene were cloned by polymerase chain
> reaction
> and inserted into an Escherichia coli expression vector which directed
> their
> expression as fusion proteins containing glutathione S-transferase at
> the N
> terminus and a flagellin fragment at the C terminus. Affinity-purified
> fusion
> proteins were assayed for reactivity on Western blots (immunoblots)
> with sera
> from patients with late-stage Lyme disease. The same immunodominant
> domain was
> bound by sera from 17 of 18 patients. This domain (comprising amino
> acids 197 to
> 241) does not share significant homology with other bacterial
> flagellins and
> therefore may be useful in serological testing for Lyme disease.
> PMID: 1894359 [PubMed - indexed for MEDLINE]
>
>
> (1992) "Western blotting in the Serodiagnosis of Lyme Disease"
> 1992, July Dressler/Steere
>
> Steere knowingly using a weakened strain intending to leave OspA and B
> out of the serologic standard, decreasing the likelihood that people
> will be diagnosed with Lyme disease, and with the intention of
> capturing all the post-LymeRIX or ImmuLyme approval testing for Lyme.
> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8380611&query_hl=7
> 1: J Infect Dis. 1993 Feb;167(2):392-400.
>
> Western blotting in the serodiagnosis of Lyme disease.
>
> Dressler F, Whalen JA, Reinhardt BN, Steere AC.
>
> Division of Rheumatology/Immunology, Tufts University School of
> Medicine, New
> England Medical Center, Boston, Massachusetts 02111.
>
> There are currently no accepted criteria for positive Western blots in
> Lyme
> disease. In a retrospective analysis of 225 case and control subjects,
> the best
> discriminatory ability of test criteria was obtained by requiring at
> least 2 of
> the 8 most common IgM bands in early disease (18, 21, 28, 37, 41, 45,
> 58, and 93
> kDa) and by requiring at least 5 of the 10 most frequent IgG bands
> after the
> first weeks of infection (18, 21, 28, 30, 39, 41, 45, 58, 66, and 93
> kDa). When
> these definitions were tested in a prospective study of all 237
> patients seen in
> a diagnostic Lyme disease clinic during a 1-year period and in 74
> patients with
> erythema migrans or summer flu-like illnesses, the IgM blot in early
> disease had
> a sensitivity of 32% and a specificity of 100%; the IgG blot after the
> first
> weeks of infection had a sensitivity of 83% and a specificity of 95%.
> Among
> patients with indeterminate IgG responses by ELISA, 6 of 9 patients
> with active
> Lyme disease had positive blots compared with 2 of 34 patients with
> other
> illnesses (P < .001). Thus, Western blotting can be used to increase
> the
> specificity of serologic testing in Lyme disease.
> PMID: 8380611 [PubMed - indexed for MEDLINE]
>
>
>
>
> (1993) "Antibody Responses to Three Genomic Groups.."
> Dressler/Steere
> 1: J Infect Dis. 1994 Feb;169(2):313-8.
> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8106763&query_hl=1
>
> Antibody responses to the three genomic groups of Borrelia burgdorferi
> in
> European Lyme borreliosis.
>
> Dressler F, Ackermann R, Steere AC.
>
> Division of Rheumatology/Immunology, New England Medical Center, Tufts
> University School of Medicine, Boston, Massachusetts 02111.
>
> The antibody responses to the three genomic groups of Borrelia
> burgdorferi (B.
> burgdorferi sensu stricto, Borrelia garinii, and Borrelia afzelii) were
> determined in 97 German patients with various manifestations of Lyme
> borreliosis. The geometric mean antibody titers in each patient group,
> determined by ELISA, were similar with each antigen preparation. By
> Western
> blotting, however, patients with meningopolyneuritis tended to respond
> to more
> spirochetal polypeptides of B. garinii, the group 2 strain, whereas
> those with
> arthritis recognized more antigens of B. afzelii, the group 3 strain (P
> < .03),
> as did those with acrodermatitis. Only 1 patient each with erythema
> migrans,
> arthritis, or acrodermatitis had weak reactivity with outer surface
> protein A
> (OspA), and none responded to OspB. It is concluded that differences
> among the
> three groups of B. burgdorferi may result in variations in the antibody
> response
> in European Lyme borreliosis. PMID: 8106763 [PubMed - indexed for
> MEDLINE]
>
>
> G39/40 is high-passage (no good)
>
> Steere demonstrates that there is a different antibody profile in
> neurologic Lyme patients,
> than there is for Lyme arthritis
>
> Sequence described by Steere, kilodaltons (kD)
>
> EARLY, with erythema migrans
> 41
>
> 1-5 months after disease onset
> 83
> 66
>
> 27
> 15
> months to years
> 75
> 60
> 34 (Osp B)
> 31 (Osp A)
> 29
> 17
>
> Page 936: 34, 31, 29, and 17 were "bound strongly," which means
> there was a high antibody concentration. This was not the case later,
> in Dressler/Steere, and OspA and B were left out of the serodiagnostic
> standard (this is "bogus" science).
> (See other notations in that text.)
>
>
> The 1994 CDC Dearborn Conference criteria are supposed to be for
> "early Lyme," but clearly "5 months to years," is not "early
> Lyme," and no one agreed with Steere, except MarDx, who had been
> given CDC Dearborn-positive arthritis blood to qualify their test kits,
> and who also have been given the contracts for both vaccine trials.
> http://www.cdc.gov/mmwr/preview/mmwrhtml/00038469.htm
>
>
> The ImmuLyme trial began in March 1994, before Dearborn even convened,
> and 6 years later, the principal investigator, Leonard Sigal reported
> that he could not even read his Western Blots, in people who were
> vaccinated.
> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9673299&query_hl=9
> 1: N Engl J Med. 1998 Jul 23;339(4):216-22.
> Erratum in:
> N Engl J Med 1998 Aug 20;339(8):571.
>
> A vaccine consisting of recombinant Borrelia burgdorferi outer-surface
> protein A
> to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme
> Disease
> Vaccine Study Consortium.
>
> Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R,
> Hilton E,
> Kunkel M, Adler-Klein D, Doherty T, Evans J, Molloy PJ, Seidner AL,
> Sabetta JR,
> Simon HJ, Klempner MS, Mays J, Marks D, Malawista SE.
>
> Department of Medicine, University of Medicine and Dentistry of New
> Jersey-Robert Wood Johnson Medical School, New Brunswick 08903-0019,
> USA.
>
> BACKGROUND: Lyme disease is a multisystem inflammatory disease caused
> by
> infection with the tick-borne spirochete Borrelia burgdorferi and is
> the most
> common vector-borne infection in the United States. We assessed the
> efficacy of
> a recombinant vaccine consisting of outer-surface protein A (OspA)
> without
> adjuvant in subjects at risk for Lyme disease. METHODS: For this
> double-blind
> trial, 10,305 subjects 18 years of age or older were recruited at 14
> sites in
> areas of the United States where Lyme disease was endemic; the subjects
> were
> randomly assigned to receive either placebo (5149 subjects) or 30
> microg of OspA
> vaccine (5156 subjects). The first two injections were administered 1
> month
> apart, and 7515 subjects also received a booster dose at 12 months. The
> subjects
> were observed for two seasons during which the risk of transmission of
> Lyme
> disease was high. The primary end point was the number of new
> clinically and
> serologically confirmed cases of Lyme disease. RESULTS: The efficacy of
> the
> vaccine was 68 percent in the first year of the study in the entire
> population
> and 92 percent in the second year among the 3745 subjects who received
> the third
> injection. The vaccine was well tolerated. There was a higher incidence
> of mild,
> self-limited local and systemic reactions in the vaccine group, but
> only during
> the seven days after vaccination. There was no significant increase in
> the
> frequency of arthritis or neurologic events in vaccine recipients.
> CONCLUSIONS:
> In this study, OspA vaccine was safe and effective in the prevention of
> Lyme
> disease. PMID: 9673299 [PubMed - indexed for MEDLINE]
>
>
>
> (1993) March, Wormser and Nowakowski: Use Western blots for ELISA
> negatives, Dressler/Steere proposal only 13-25% accurate. (The
> standard adopted by the CDC is the opposite- It says not to do a
> Western Blot on ELISA negatives.)
>
> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8308100&query_hl=11
>
> 1: J Clin Microbiol. 1993 Dec;31(12):3090-5.
>
> Erratum in:
> J Clin Microbiol 1994 Mar;32(3):860.
>
> Serodiagnosis in early Lyme disease.
>
> Aguero-Rosenfeld ME, Nowakowski J, McKenna DF, Carbonaro CA, Wormser
> GP.
>
> Department of Pathology, New York Medical College, Valhalla.
>
> Using a commercially available enzyme-linked immunosorbent assay
> (ELISA) and an
> immunoblot assay (IB), we tested sera from 100 patients with erythema
> migrans
> (EM) seen in 1991 a the Westchester County Medical Center Lyme Disease
> Diagnostic Center. Convalescent-phase sera were available from 59
> patients.
> Fifty-five patients had EM of < 7 days' duration, 31 had EM of 7 to 14
> days'
> duration, and 14 had EM of > 14 days' duration. During the acute phase
> of
> infection, 35 patients had a positive ELISA result and 43 had a
> positive IB
> result by the recently published criteria of Dressler et al. (F.
> Dressler, J. A.
> Whalen, B. N. Reinhardt, and A. C. Steere, J. Infect. Dis. 167:392-400,
> 1993)
> for interpretation of IB in patients with Lyme disease. A greater
> sensitivity of
> IB was observed in patients with EM of < 7 days' duration, as follows:
> 14 of 55
> (25%) for IB versus 7 of 55 (13%) for ELISA (P = 0.144). Sera of all 14
> patients
> with EM of > 14 days' duration were reactive by both tests, as follows:
> 13
> positive and 1 equivocal by ELISA and 12 positive and 2 indeterminate
> by the IB.
> The band reactivity most frequently observed in the IB was to the 41-
> and 25-kDa
> antigens, the latter being the most frequent band observed in
> immunoglobulin M
> blots. Seroconversion was observed in 74 and 64% of evaluable patients
> by ELISA
> and IB, respectively, despite the use of antibiotic therapy.
> PMID: 8308100 [PubMed - indexed for MEDLINE]
>
>
>
>
> (1993) "Overdiagnosis" article, Steere Patients not positive
> "in our labs" - using bogus strains (high-passage G39/40, and
> FRG- a German strain)
>
> Most people will not have antibodies to these weakened or useless
> strains.
>
> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8459513&query_hl=13
>
> 1: JAMA. 1993 Apr 14;269(14):1812-6.
>
> The overdiagnosis of Lyme disease.
>
> Steere AC, Taylor E, McHugh GL, Logigian EL.
>
> Division of Rheumatology/Immunology, New England Medical Center,
> Boston, MA
> 02111.
>
> OBJECTIVE--To analyze the diagnoses, serological test results, and
> treatment
> results of the patients evaluated in a Lyme disease clinic, both prior
> to
> referral and from current evaluation. DESIGN--Retrospective case survey
> of
> prescreened patients. SETTING--Research and diagnostic Lyme disease
> clinic in a
> university hospital. PATIENTS--All 788 patients referred to the clinic
> during a
> 4.5-year period who were thought by the referring physician or the
> patient to
> have a diagnosis of Lyme disease.
> MAIN OUTCOME MEASUREMENTS--Symptoms and signs
> of disease, immunodiagnostic tests of Lyme disease, and tests of
> neurological
> function. RESULTS--Of the 788 patients, 180 (23%) had active Lyme
> disease,
> usually arthritis, encephalopathy, or polyneuropathy. One hundred
> fifty-six
> patients (20%) had previous Lyme disease and another current illness,
> most
> commonly chronic fatigue syndrome or fibromyalgia; and in 49 patients,
> these
> symptoms began soon after objective manifestations of Lyme disease. The
> remaining 452 patients (57%) did not have Lyme disease. The majority of
> these
> patients also had the chronic fatigue syndrome or fibromyalgia; the
> others
> usually had rheumatic or neurological diseases. Of the patients who did
> not have
> Lyme disease, 45% had had positive serological test results for Lyme
> disease in
> other laboratories, but all were seronegative in our laboratory. Prior
> to
> referral, 409 of the 788 patients had been treated with antibiotic
> therapy. In
> 322 (79%) of these patients, the reason for lack of response was
> incorrect
> diagnosis. CONCLUSIONS--Only a minority of the patients referred to the
> clinic
> met diagnostic criteria for Lyme disease. The most common reason for
> lack of
> response to antibiotic therapy was misdiagnosis.
> PMID: 8459513 [PubMed - indexed for MEDLINE]
>
>
>
>
> (1993, Dec) US PATENT- Fikrig (Yale) 5618533 Bb Flagellin (94%
> accurate, early, and specific test)
>
> http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/srchnum.htm&r=1&f=G&l=50&s1=5618533.WKU.&OS=PN/5618533&RS=PN/5618533
>
> United States Patent 5,618,533
> Flavell , et al. April 8, 1997
>
> Flagellin-based polypeptides for the diagnosis of lyme disease
> Abstract
> Diagnostic means and methods for Lyme disease comprising B. burgdorferi
> flagellin polypeptides and antibodies. Compositions and methods
> comprising neuroborreliosis-associated antigens useful for the
> detection, treatment and prevention of neuroborreliosis, arthritis,
> carditis and other manifestations of Lyme disease.
> Inventors: Flavell; Richard A. (Killingworth, CT); Fikrig; Erol
> (Guilford, CT); Berland; Robert (Kingston, NY) Assignee: Yale
> University (New Haven, CT) Appl. No.: 166160 Filed: December 10, 1993
>
>
> 1994, March through 1999, August- the ImmuLyme trial- A MUST READ
>
>
> 1994 June- FDA Meeting, Ray Dattwyler recommends using serial
> Western Blots to assesss vaccines.
>
>
> (1994, Oct 7) US PATENT- 5747294 Yale's OspA patent
>
> http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/srchnum.htm&r=1&f=G&l=50&s1=5747294.WKU.&OS=PN/5747294&RS=PN/5747294
>
> United States Patent 5,747,294
> Flavell , et al. May 5, 1998
>
> Compositions and methods for the prevention and diagnosis of lyme
> disease
> Abstract
> Methods and compositions for the prevention and diagnosis of Lyme
> disease. OspA and OspB polypeptides and serotypic variants thereof,
> which elicit in a treated animal the formation of an immune response
> which is effective to treat or protect against Lyme disease as caused
> by infection with B. burgdorferi. Anti-OspA and anti-OspB antibodies
> that are effective to treat or protect against Lyme disease as caused
> by infection with B. burgdorferi. A screening method for the selection
> of those OspA and OspB polypeptides and anti-OspA and anti-OspB
> antibodies that are useful for the prevention and detection of Lyme
> disease. Diagnostic kits including OspA and OspB polypeptides or
> antibodies directed against such polypeptides.
>
> Inventors: Flavell; Richard A. (Killingworth, CT); Kantor; Fred S.
> (Orange, CT); Barthold; Stephen W. (Madison, CT); Fikrig; Erol
> (Guilford, CT)
> Assignee: Yale University (New Haven, CT)
> Appl. No.: 320161
> Filed: October 7, 1994
>
>
> "Early in human infection, antibodies are generated primarily against
> a 41 kD flagella-associated antigen. Later on, high titers appear to
> both OspA and OspB..."
>
>
> (1994, Oct) Dearborn, MI CDC Conference data: Recommendations: DO
> NOT USE HIGH PASSAGE STRAINS
>
> Lists interest-conflicted parties
>
>
> See my Jan 2001 FDA testimony (How to pass off a bogus vaccine: Make
> its failure undetectable):
>
> http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2_11.pdf
>
>
>
> (1996, March) US PATENT- 6045804 Persing (Corixa) OspA-less
> spirochete
>
> United States Patent 6,045,804
> Persing April 4, 2000
>
> Method for detecting B. burgdorferi infection
> Abstract
> The present invention provides a method for detecting B. burgdorferi
> infection utilizing an antigen preparation lacking a detectable level
> of outer surface protein A (OspA). The antigen preparation is made from
> an isolate of B. burgdorferi that lacks the plasmid encoding outer
> surface protein A (OspA). The method of the invention discriminates B.
> burgdorferi infection from OspA vaccination.
>
> Inventors: Persing; David H. (Rochester, MN)
> Assignee: Mayo Foundation for Medical Educational Research (Rochester,
> MN)
> Appl. No.: 612231
> Filed: March 7, 1996
>
>
>
> -Mentions problems with Immunoblotting
>
> - Mentions there is a need for a test to detect Lyme in vaccinated and
> non-vaccinated patients- WHICH IS THE ENTIRE NATURE OF THIS SCAM.
>
> -Evidence of "partnership" between SmithKline, Corixa and Imugen
> (also L2 Diagnostics, the Yale Lyme and Lupus clinic biotech spinoff.
> This spinoff firm was funded by the Yale Endowment fund.
>
>
> 2000, "Detection of Multiple Reactive Species..." (Imugen's
> Phillip Molloy,
> Victor Berardi, and Leonard Sigal, with Dave Persing.).
>
> http://www.journals.uchicago.edu/CID/journal/issues/v31n1/991200/991200.html?erFrom=-3186362707054415028Guest
>
>
> Why weren't these unreadable blots reported to the FDA, and how could
> Sigal have reported a 92% safe and effective vaccine with unreadable
> blots?
>
> Or is this just a promotion for use of their patented test, for which
> only Imugen and L2 Diagnostics are licensed from Corixa to use?
> http://www.yale.edu/opa/newsr/98-12-22-01.all.html
>
> Yale, SmkithKline, Corixa, Imugen-THE PARTNERSHIP:
>
> http://www.imugen.com/news_release1.htm
>
> http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=149722&tools=bot
>
> Please see my notes in that report
>
>
> Henry Feder (UCONN) ran a vaccine trial on European children, when
> there is practically none of that kind of OspA in Europe, according to
> Steere.
> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10547245&query_hl=1
>
>
> 1: J Pediatr. 1999 Nov;135(5):575-9.
>
> Comment in:
> J Pediatr. 1999 Nov;135(5):539-41.
> J Pediatr. 2001 Apr;138(4):609-10.
>
> Immunogenicity of a recombinant Borrelia burgdorferi outer surface
> protein A
> vaccine against Lyme disease in children.
>
> Feder HM Jr, Beran J, Van Hoecke C, Abraham B, De Clercq N, Buscarino
> C, Parenti
> DL.
>
> Department of Family Medicine, University of Connecticut Health Center,
> Farmington, Connecticut 06030-1406, USA.
>
> BACKGROUND AND OBJECTIVE: A recombinant lipoprotein vaccine against
> Lyme
> disease, containing 30 microg of Borrelia burgdorferi outer surface
> protein A
> (OspA) with aluminum adjuvant, has been shown in a large US field trial
> of
> subjects >/=15 years of age to offer 76% efficacy against clinical Lyme
> disease
> after 3 injections given at 0, 1, and 12 months. Lyme disease is also
> an
> important problem in children; thus, OspA vaccine trials in children
> are needed.
> The purpose of this study was to investigate the safety and
> immunogenicity of 2
> different doses of lipoprotein OspA with aluminum adjuvant vaccine in
> healthy
> children 5 to 15 years of age in a double-blind, randomized study.
> STUDY DESIGN:
> In a double-blind study, 250 children from the Czech Republic were
> randomly
> assigned to receive 15 microg or 30 microg of OspA vaccine at 0, 1, and
> 2
> months. Serum samples, obtained before vaccination and 1 month after
> the second
> and third doses, were analyzed for antiOspA antibody. Solicited and
> unsolicited
> symptoms were collected from diary cards. RESULTS: Local pain at the
> injection
> site was reported by approximately 76% of the 250 children. Headaches
> (after 5%
> to 18% of the injections) and malaise (after 2% to 16% of the
> injections) were
> the most frequently reported general symptoms. Local and generalized
> symptoms
> were not different between the 15 microg and 30 microg groups, and all
> symptoms
> resolved within 4 days. Both doses were highly immunogenic, with the 30
> microg
> dose eliciting higher antibody levels. Seroconversion occurred in 99%
> of the 250
> children. CONCLUSIONS: The OspA vaccine against Lyme disease was well
> tolerated
> and highly immunogenic in children.
> PMID: 10547245 [PubMed - indexed for MEDLINE]
>
>
>
>
> 2005, Feb- CDC releases more of their nonsense about what is a valid
> test, and imply that we need "use of validated laboratory tests,"
> but CDC's are hardly valid, FDA's own criteria.
>
> http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5405a6.htm
>
>
> 2005, May, Reponse to Dr. Raphael Stricker in which he states: "To
> my knowledge, the CDC website does not state that the serological
> criteria recommended by the CDC are not appropriate for use in clinical
> diagnosis."
>
> "Clinical" means signs and symptoms, independent of lab work.
>
> It is on the Department of Health and Human Services' website, in
> which CDC states that there is no substitute for sound clinical
> judgment: PAUL MEAD: "For this reason, CDC has repeatedly stated
> that the surveillance case definition is not a substitute for sound
> clinical judgment."
> http://www.hhs.gov/asl/testify/t040129.html

.

Relevant Pages